Jerusalem-based Teva Pharmaceutical Industries Ltd. announced Monday that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion.
A year after the FDA rejected Cell Therapeutics Inc.'s (CTI) pixantrone application for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL), the Office of New Drugs (OND) has denied an appeal request from CTI, which claimed the drug showed efficacy.
Jerusalem's Teva Pharmaceutical Industries Ltd., announced this morning that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion.
Regeneron Pharmaceuticals Inc.'s (Nasdaq:RGEN) stock surged 28 percent on news that its Phase III VELOUR trial of Zaltrap (aflibercept) for metastatic colon cancer hit its primary endpoint of improving overall survival. Regeneron and partner Sanofi-Aventis will waste no time preparing marketing approval applications for the FDA and European Medicines Agency for submission in the second half of 2011.
Endocyte Inc.'s stock jumped 25 percent Tuesday on news that it would be applying for marketing authorization from the European Medicines Agency for two of its products: ovarian cancer candidate EC145 and a companion imaging diagnostic EC20 for patient selection.
Powerful multidrug cocktails are critically important for battling multidrug-resistant tuberculosis (TB). Industry is working hard to develop new drugs that will not only work well individually, but synergistically, creating an effect where the whole is more than the sum of the parts.
Weak sales of its HIV drugs in the U.S. pushed Gilead Sciences Inc.'s earnings down in the first quarter. Revenues of $1.93 billion were below consensus estimates and down 8 percent from the first quarter of 2010.
Baxter International Inc., of Deerfield, Ill., will acquire Prism Pharmaceuticals Inc., of King of Prussia, Pa., for a total consideration of $338 million.
A little over a year after its $35 million Series B financing, bluebird bio has returned for another $30 million, laying down a three-year cash runway for advancement of its gene therapy products for rare diseases. CEO Nick Leschly calls the financing, which brings in new investor ARCH Venture Partners, "opportunistic." Existing investors Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group also participated.
